NCT06330545 Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release
| NCT ID | NCT06330545 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Condition | Dupuytren Contracture |
| Study Type | INTERVENTIONAL |
| Enrollment | 95 participants |
| Start Date | 2024-09-16 |
| Primary Completion | 2029-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 95 participants in total. It began in 2024-09-16 with a primary completion date of 2029-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are: • Does targeted radiation therapy decrease recurrence of Dupuytren's contracture after treatment with Collagenase Clostridium Histolyticum? Participants will undergo: * Release of Dupuytren's Contracture after Collagenase Clostridium Histolyticum injection * Daily radiation therapy treatment for 5 days followed by 6-8 week rest period and then another course of 5 days of radiation therapy
Eligibility Criteria
Inclusion Criteria: * Age 45 or greater with DC * Extension deficit \>10 degrees * Unable to simultaneously place the affected finger and palm flat on a table. * Women included in the study will be post-menopausal or using contraception, and a pregnancy test will be performed as standard of care. * For patients who are having multiple CCH injections, only the first 2 joints on given hand will be included Exclusion Criteria: * Unsuccessful non-surgical release (\> N/1 disease) * They develop an open wound during CCH * Breast feeding or pregnancy * A chronic muscular, neurologic, or neuromuscular disorder affecting the hands. * Less than the age of 45 * They have previously undergone radiation on the hand in which they plan to get CCH injections * They are pregnant women, impaired adults or prisoners
Contact & Investigator
Lance Warhold, MD
PRINCIPAL INVESTIGATOR
Dartmouth Health
Frequently Asked Questions
Who can join the NCT06330545 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Dupuytren Contracture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06330545 currently recruiting?
Yes, NCT06330545 is actively recruiting participants. Contact the research team at julia.s.schwarz@hitchcock.org for enrollment information.
Where is the NCT06330545 trial being conducted?
This trial is being conducted at Lebanon, United States.
Who is sponsoring the NCT06330545 clinical trial?
NCT06330545 is sponsored by Dartmouth-Hitchcock Medical Center. The principal investigator is Lance Warhold, MD at Dartmouth Health. The trial plans to enroll 95 participants.